The Chemours Company

NYSE:CC 株式レポート

時価総額：US$2.4b

Chemours 過去の業績

過去 基準チェック /06

Chemoursの収益は年間平均-59.8%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間3.4% 2.7%割合で 減少しています。

主要情報

-59.83%

収益成長率

-59.15%

EPS成長率

Chemicals 業界の成長12.93%
収益成長率-2.67%
株主資本利益率n/a
ネット・マージン-5.24%
前回の決算情報30 Jun 2026

最近の業績更新

Recent updates

Seeking Alpha • Aug 06

Chemours: Close To A 'Perfect' Rotation, With A 'Buy' In Q2 2026 (Rating Upgrade)

Summary Chemours is upgraded to 'BUY' with a $20 PT and $30 fair value, reflecting renewed upside after recent volatility. CC's recent rally was driven by sentiment, not fundamentals, but the company now shows improving liquidity, debt reduction, and solid EBITDA guidance. Risks remain from regulatory liabilities and elevated leverage, but CC's divestment plan and Opteon growth support a high-conviction turnaround thesis. At or below $15/share, CC offers 35-37% annual upside; at $20/share, the risk/reward remains attractive though more speculative. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 05

CC: PFAS Settlement Will Support Cleaner Operations And Stronger Future Outlook

Analysts have trimmed their Chemours price target from $21.00 to $19.00 as updated assumptions point to different expectations for fair value, profitability, growth and future P/E levels. What’s in the News for Chemours Chemours announced a settlement with the U.S. Environmental Protection Agency and the West Virginia Department of Environmental Protection to resolve claims related to PFAS discharges and other alleged non compliance at its Washington Works, Fayetteville Works, and Chambers Works facilities.
ナラティブ更新 • Jul 22

CC: Regulatory Settlement And Margin Recovery Will Drive Re Rating Potential

Analysts have lowered their price target on Chemours to $24.67 from $26.33, citing updated assumptions that include a slightly higher discount rate, modestly adjusted revenue growth expectations, a small change in projected profit margins, and a revised future P/E multiple. What’s in the News for Chemours BMO Capital reiterated a Buy rating on Chemours with a US$26 price target, which is close to the current median Wall Street target of US$25, according to recent analyst reports.
ナラティブ更新 • Jul 06

CC: PFAS Settlement And Updated Outlook Will Shape Balanced Future Expectations

Analysts have raised their Chemours fair value estimate from $17.00 to $21.00, citing updated views on discount rate assumptions, revenue growth, profit margins and potential future P/E levels. What’s in the News for Chemours Chemours agreed to a multi-site PFAS settlement with the U.S. Environmental Protection Agency, the Department of Justice, the West Virginia Department of Environmental Protection, and multiple states, with total costs reported at more than US$450 million for penalties, mitigation projects, pollution controls, and community water initiatives.
ナラティブ更新 • Jun 22

CC: Raised Margins And 2026 Outlook Will Support Further Earnings Upside

Analysts maintained their $30.00 price target on Chemours, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that together support keeping the prior valuation level. What’s in the News for Chemours Chemours issued earnings guidance for the second quarter of 2026, indicating an expected sequential change in consolidated net sales in a range of 15% to 20%, which the company links to seasonal trends.
ナラティブ更新 • Jun 04

CC: Regulatory Reset And Margin Rebound Will Drive Re Rating Potential

Analysts now cite improved assumptions for Chemours' fair value, discount rate, revenue growth, profit margin, and future P/E in raising their price target by about $10 per share. What's in the News Chemours shares fell on May 21, 2026 after the EPA eased refrigerant regulations put in place during the Biden administration, according to recent news reports.
ナラティブ更新 • May 15

CC: Cooling Alliance And 2026 Guidance Will Support Further Earnings Upside

Analysts have raised their price target for Chemours by $1 to $30, reflecting updated assumptions that include a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E estimate. What's in the News Chemours issued earnings guidance for the second quarter of 2026, expecting consolidated net sales to be 15% to 20% higher sequentially, citing favorable seasonal trends (Corporate Guidance).
分析記事 • May 08

The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

It's been a mediocre week for The Chemours Company ( NYSE:CC ) shareholders, with the stock dropping 17% to US$22.41 in...
ナラティブ更新 • Apr 22

CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside

Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).
ナラティブ更新 • Apr 08

CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside

Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).
ナラティブ更新 • Mar 24

CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership

Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).
ナラティブ更新 • Mar 09

CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook

Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.
ナラティブ更新 • Feb 22

CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside

Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.
ナラティブ更新 • Feb 08

CC: PFAS Class Action Risk Will Limit Future Shareholder Returns

Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.
分析記事 • Feb 03

The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth

The The Chemours Company ( NYSE:CC ) share price has done very well over the last month, posting an excellent gain of...
ナラティブ更新 • Jan 25

CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook

Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).
ナラティブ更新 • Jan 11

CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns

Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.
ナラティブ更新 • Dec 26

CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks

Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).
ナラティブ更新 • Dec 12

CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks

Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).
ナラティブ更新 • Nov 01

CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher

Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.
ナラティブ更新 • Oct 17

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).
ナラティブ更新 • Oct 03

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).
ナラティブ更新 • Sep 17

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.
分析記事 • Sep 03

The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

The Chemours Company ( NYSE:CC ) shares have continued their recent momentum with a 33% gain in the last month alone...
分析記事 • Jul 26

Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

The Chemours Company ( NYSE:CC ), is not the largest company out there, but it saw a significant share price rise of...
分析記事 • Jul 04

The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

The Chemours Company ( NYSE:CC ) shares have had a really impressive month, gaining 30% after a shaky period...
分析記事 • Jun 29

Chemours (NYSE:CC) Has No Shortage Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • May 14

We Like The Quality Of Chemours' (NYSE:CC) Earnings

Despite posting healthy earnings, The Chemours Company's ( NYSE:CC ) stock has been quite weak. Along with the solid...
分析記事 • Apr 25

Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

Key Insights The projected fair value for Chemours is US$23.71 based on 2 Stage Free Cash Flow to Equity Chemours is...

収支内訳

Chemours の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NYSE:CC 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 265,797-304621106
31 Mar 265,821-410528107
31 Dec 255,808-386504108
30 Sep 255,837-337549107
30 Jun 255,850-429578111
31 Mar 255,78810603108
31 Dec 245,78269618109
30 Sep 245,83563557109
30 Jun 245,814106505107
31 Mar 245,904-329538110
31 Dec 236,078-2531,286108
30 Sep 236,004-317567112
30 Jun 236,294-87624117
31 Mar 236,566489689114
31 Dec 226,831578705118
30 Sep 227,031908688117
30 Jun 226,933881670111
31 Mar 226,673746560113
31 Dec 216,345608583107
30 Sep 216,108394582104
30 Jun 215,662256572100
31 Mar 215,10021553993
31 Dec 204,96921952693
30 Sep 204,984-11746386
30 Jun 205,140-11747283
31 Mar 205,455-4650882
31 Dec 195,526-5253680
30 Sep 195,63740760082
30 Jun 195,87660661083
31 Mar 196,28479264784
31 Dec 186,63899563082
30 Sep 186,7491,08160380
30 Jun 186,7051,01359780
31 Mar 186,47689357882
31 Dec 176,18374659281
30 Sep 175,93028858282
30 Jun 175,74428560581
31 Mar 175,54010661676
31 Dec 165,400759181
30 Sep 165,43815160589
30 Jun 165,526-8261587
31 Mar 165,651-8259897
31 Dec 155,717-9063297
30 Sep 155,90675634101

質の高い収益: CCは現在利益が出ていません。

利益率の向上: CCは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CCは利益が出ておらず、過去 5 年間で損失は年間59.8%の割合で増加しています。

成長の加速: CCの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CCは利益が出ていないため、過去 1 年間の収益成長をChemicals業界 ( -0.9% ) と比較することは困難です。

株主資本利益率

高いROE: CCの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/09 02:43
終値2026/08/07 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

The Chemours Company 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18

アナリスト機関
null nullAlembic Global Advisors
David ColemanArgus Research Company
Michael LeitheadBarclays